1156-19-0
Chemical Structure
Tolazamide
Synonym(s): U-17835
- CAS No.: 1156-19-0
- Formula:C14H21N3O3S
- Molecular Weight:311.40
IUPAC Name: N-(azepan-1-ylcarbamoyl)-4-methylbenzenesulfonamide
InChIKey: OUDSBRTVNLOZBN-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(C)C=C1)(NC(NN2CCCCCC2)=O)=O
Biological Activity: Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tolazamide | 99.94% | Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolazamide (Standard) | ≥98% | Tolazamide (U-17835) (Standard) is the analytical standard of Tolazamide. This product is intended for research and analytical applications. Tolazamide is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Mustafa Karakaya, et al., (2015) Theoretical and experimental investigations on vibrational and structural properties of tolazamide, Journal of Molecular Structure, Volume 1095, Pages 87-95, ISSN 0022-2860.
- [2]. Gopalakrishnan, M., et al., (2000). Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells. British journal of pharmacology, 129(7), 1323–1332. [Content Brief]
- [3]. Kabadi U. M. (1985). Adjuvant therapy with tolazamide and insulin improves metabolic control in type I diabetes mellitus. Diabetes care, 8(5), 440–446. [Content Brief]
Keywords
